> Detailanzeige

Cortellini, Alessio; Buti, Sebastiano; Santini, Daniele; Perrone, Fabiana; Giusti, Raffaele; Tiseo, Marcello; Bersanelli, Melissa; Michiara, Maria; Grassadonia, Antonino; Brocco, Davide; Tinari, Nicola; De Tursi, Michele; Zoratto, Federica; Veltri, Enzo; Marconcini, Riccardo; Malorgio, Francesco; Garufi, Carlo; Russano, Marco; Anesi, Cecilia; Zeppola, Tea; Filetti, Marco; Marchetti, Paolo; Botticelli, Andrea; Antonini Cappellini, Gian Carlo; [...]

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study
  • Beteiligte: Cortellini, Alessio; Buti, Sebastiano; Santini, Daniele; Perrone, Fabiana; Giusti, Raffaele; Tiseo, Marcello; Bersanelli, Melissa; Michiara, Maria; Grassadonia, Antonino; Brocco, Davide; Tinari, Nicola; De Tursi, Michele; Zoratto, Federica; Veltri, Enzo; Marconcini, Riccardo; Malorgio, Francesco; Garufi, Carlo; Russano, Marco; Anesi, Cecilia; Zeppola, Tea; Filetti, Marco; Marchetti, Paolo; Botticelli, Andrea; Antonini Cappellini, Gian Carlo; [...]
  • Erschienen: Oxford University Press (OUP), 2019
  • Erschienen in: The Oncologist
  • Sprache: Englisch
  • DOI: 10.1634/theoncologist.2018-0618
  • ISSN: 1083-7159; 1549-490X
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Patients with a history of autoimmune diseases (AIDs) have not usually been included in clinical trials with immune checkpoint inhibitors.</jats:p> </jats:sec> <jats:sec> <jats:title>Materials and Methods</jats:title> <jats:p>Consecutive patients with advanced cancer, treated with anti-programmed death-1 (PD-1) agents, were evaluated according to the presence of pre-existing AIDs. The incidence of immune-related adverse events (irAEs) and clinical outcomes were compared among subgroups.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>A total of 751 patients were enrolled; median age was 69 years. Primary tumors were as follows: non-small cell lung cancer, 492 (65.5%); melanoma, 159 (21.2%); kidney cancer, 94 (12.5%); and others, 6 (0.8%). Male/female ratio was 499/252. Eighty-five patients (11.3%) had pre-existing AIDs, further differentiated in clinically active (17.6%) and inactive (82.4%). Among patients with pre-existing AIDs, incidence of irAEs of any grade was significantly higher when compared with patients without AIDs (65.9% vs. 39.9%). At multivariate analysis, both inactive (p = .0005) and active pre-existing AIDs (p = .0162), female sex (p = .0004), and Eastern Cooperative Oncology Group Performance Status &amp;lt;2 (p = .0030) were significantly related to a higher incidence of irAEs of any grade. No significant differences were observed regarding grade 3/4 irAEs and objective response rate among subgroups. Pre-existing AIDs were not significantly related with progression-free survival and overall survival.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>This study quantifies the increased risk of developing irAEs in patients with pre-existing AIDs who had to be treated with anti-PD-1 immunotherapy. Nevertheless, the incidence of grade 3/4 irAEs is not significantly higher when compared with control population. The finding of a greater incidence of irAEs among female patients ranks among the “hot topics” in gender-related differences in immuno-oncology.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang